News & Events
- Genetic Analysis presents at Mangold Insight’s Investor Day
- Seres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference
- Seres Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
- Seres Therapeutics to Host Fourth Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on March 7, 2023
- Seres Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
- Year-end report January – December 2022
- Seres Therapeutics’ Investigational SER-109 ECOSPOR IV Study Data Published in JAMA NETWORK OPEN
- Seres Therapeutics Announces Initiation of Enrollment in SER-155 Phase 1b Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
- Genetic Analysis strengthens and future-proofs the organization
- Genetic Analysis’ CTO finalist in the Lyfebulb and Bristol Myers Squibb Innovation Challenge addressing unmet needs in IBD
- Genetic Analysis AS achieves Thai FDA License for GA-map[®] Dysbiosis Test in Thailand
- Genetic Analysis AS achieves Thai FDA License for GA-map® Dysbiosis Test in Thailand
- Genetic Analysis AS enters an agreement with Microbiome Research Pvt. Ltd. to launch GA-map[®] technology in India
- Genetic Analysis AS enters an agreement with Microbiome Research Pvt. Ltd. to launch GA-map® technology in India
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)